An immunogenic first-in-human immune modulatory vaccine with PD-L1 and PD-L2 peptides is feasible and shows early signs of efficacy in follicular lymphoma.
Klausen U, Grønne Dahlager Jørgensen N, Grauslund JH, Munir Ahmad S, Gang AO, Martinenaite E, Weis-Banke SE, Breinholt MF, Novotny GW, Kjeldsen JW, Orebo Holmström M, Pedersen LB, Poulsen CB, Hansen PB, Met Ö, Svane IM, Niemann CU, Pedersen LM, Andersen MH.
Klausen U, et al. Among authors: gang ao.
Oncoimmunology. 2021 Sep 25;10(1):1975889. doi: 10.1080/2162402X.2021.1975889. eCollection 2021.
Oncoimmunology. 2021.
PMID: 38283034
Free PMC article.